News Center

位置：

Honors Announcement

Group News

Media Reports

Shisi Pharmaceutical Ranked Among Hurun China’s Top 100 Private Healthcare Companies in 2020

Category:

Honors Announcement

发布时间：2020-03-23

【概要描述】 Under the COVID-19 pandemic, the greater health industry has garnered significant attention. On March 18, the Hurun Research Institute released its inaugural “2020 Hurun Top 100 Private Greater Health Enterprises” ranking, which ranks 100 leading private companies in the greater health sector based on their market capitalization or valuation. Shisi Pharmaceutical Group ranked 83rd on the list with a market capitalization of RMB 18 billion.

Amid the COVID-19 pandemic, the greater health industry has garnered significant attention. On March 18, the Hurun Research Institute released its inaugural “2020 Hurun Top 100 Private Greater Health Enterprises” ranking, which ranks 100 leading private companies in the greater health sector based on their market capitalization or valuation. Shisi Pharmaceutical Group ranked 83rd on the list, with a market capitalization of RMB 18 billion.

Rupert Hoogewerf, Chairman and Chief Research Officer of Hurun Report, explained that in this ranking, “Chinese private enterprises” refers to non-state-owned companies headquartered in mainland China. For listed companies, market capitalization is calculated based on the closing prices as of February 28, 2020; for unlisted companies, valuations are estimated by referencing comparable listed firms in the same industry. According to research data from the Hurun Research Institute, China’s greater health sector has experienced rapid growth over the past decade. With the acceleration of China’s healthcare reform, the sector’s value has grown fivefold compared with five years ago and tenfold compared with ten years ago.

“This COVID-19 pandemic has brought unprecedented public attention to the greater health industry, as people are looking to these companies to help provide treatment protocols, protective supplies, and enhanced services. Today, these firms must not only serve the domestic market but also meet the substantial demand in overseas markets,” Hu Run noted.

Shisi Pharmaceutical Group is a high-tech enterprise that integrates the development of chemical pharmaceuticals, traditional Chinese patent medicines, active pharmaceutical ingredients, pharmaceutical packaging materials, and the health industry. The company has steadily increased its investment in industrial innovation year after year, rapidly enhancing its market influence and competitiveness, and has thus garnered widespread attention across the industry. Currently, Shisi Pharmaceutical Group’s flagship injectable products are distributed nationwide and are marketed in more than 80 countries and regions worldwide. During the COVID-19 pandemic, the company promptly provided emergency medicines to front-line epidemic control efforts and made generous donations, thereby earnestly fulfilling its social responsibility.